Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
Cancer, 07/01/09
Jain N et al. - The current data suggested that vaccination-related transient disruption of immune tolerance may contribute to the reduction in Bcr-Abl transcripts. Clinically, this Bcr-Abl peptide vaccine may transiently improve the molecular response in a subset of patients with CML.
Related Articles
Daunorubicin Versus Mitoxantrone Versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
Journal of Clinical Oncology, 10/23/09
Relevance Score: 91%
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives
Current Opinion in Oncology, 10/14/09
Relevance Score: 90%
Genetic lesions in chronic lymphocytic leukemia: clinical implications
Current Opinion in Oncology, 10/14/09
Relevance Score: 89%
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP
Blood, 10/09/09
Relevance Score: 89%
Minor histocompatibility antigens-targets of graft versus leukemia responses
International Journal of Hematology, 10/07/09
Relevance Score: 89%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway
Carcinogenesis, 12/15/09
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial
Annals of Oncology, 12/15/09
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkins lymphoma
European Journal of Haematology, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


